Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioNxt Solutions Inc C.BNXT

Alternate Symbol(s):  BNXTF

BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active... see more

CSE:BNXT - Post Discussion

BioNxt Solutions Inc > 30 days are up !! News?
View:
Post by jenkinjt on Oct 09, 2020 5:03pm

30 days are up !! News?

NR Sept. 8th: "3a has taken possession of COVID-19 RNA isolated from live viable virus for its second round of proof of concept prototype testing. This evaluation process is currently underway and results are expected within 30 days."

Please post results... Thanks
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities